Venlafaxine for Non-specific Low Back Pain
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing Tiantan Hospital
About this trial
Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug Venlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.
Eligibility criteria
Qualifiers
Adults aged 18 to 75 years.
Diagnosis of chronic nonspecific low back pain, defined as pain located below the costal margin and above the inferior gluteal folds, lasting for more than 3 months, without a specific pathological cause.
Moderate to severe pain, defined as a Numerical Rating Scale score of 3 or higher.
Able to understand the study procedures and sign written informed consent.
Disqualifiers
Low back pain caused by a known specific pathological condition, including but not limited to fracture, malignancy, infection, inflammatory disease, or other identifiable structural or systemic causes.
Major comorbidities that may interfere with study outcomes or represent contraindications to the study medication.
Current or previous diagnosis of depression, regardless of whether treatment was received.
Current or previous use of antidepressant medication.
Trial design
Treatments tested in this trial
- Control Group
- Venlafaxine group
Treatment groups
228 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov